Who are Metronidazole 250 (7 days)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Metronidazole Tablet, Fexinidazole, Solosec, Pylera, BISMUTH SUBCITRATE POTASSIUM, Tindamax.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metronidazole-250-7-days.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Metronidazole 250 (7 days) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metronidazole 250 (7 days) (Metronidazole 250 (7 days)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nitroimidazole antimicrobial. Area: Infectious Disease.

marketed Nitroimidazole antimicrobial Bacterial and parasitic DNA Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Metronidazole 250 (7 days) (Metronidazole 250 (7 days)) — University of Guarulhos. Metronidazole disrupts bacterial and parasitic DNA by generating reactive oxygen species and damaging their genetic material.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Metronidazole 250 (7 days) TARGET	Metronidazole 250 (7 days)	University of Guarulhos	marketed	Nitroimidazole antimicrobial	Bacterial and parasitic DNA
Metronidazole Tablet	Metronidazole Tablet	Appili Therapeutics Inc.	marketed	Nitroimidazole antibiotic	Bacterial and parasitic DNA
Fexinidazole	FEXINIDAZOLE	Sanofi	marketed	Nitroimidazole Antimicrobial [EPC]		2021-01-01
Solosec	SECNIDAZOLE	Evofem Inc	marketed	Nitroimidazole Antimicrobial [EPC]		2017-01-01
Pylera	BISMUTH SUBCITRATE		marketed	Nitroimidazole Antimicrobial [EPC]		2006-01-01
BISMUTH SUBCITRATE POTASSIUM	BISMUTH SUBCITRATE POTASSIUM		marketed	Nitroimidazole Antimicrobial [EPC]		2006-01-01
Tindamax	TINIDAZOLE	Mission Pharma	marketed	Nitroimidazole Antimicrobial [EPC]		2004-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nitroimidazole antimicrobial class)

Galderma R&D · 2 drugs in this class
University of Guarulhos · 2 drugs in this class
Jinnah Postgraduate Medical Centre · 1 drug in this class
Peking University Shenzhen Hospital · 1 drug in this class
University of Toronto · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Metronidazole 250 (7 days) — Competitive Intelligence Brief. https://druglandscape.com/ci/metronidazole-250-7-days. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab